An inspiring play about Parkinson’s and Parkour is coming to a theatre near you
Author: Geoffrey ChangPublished: 8 September 2016
Prep: Cook: Serves:
A new thought-provoking play that explores the friendship between a free-running teenager and a woman with early-onset Parkinson’s is going on a nationwide tour
After three sell-out shows in cities across the UK and rave reviews, a new Parkinson’s play called Kinetics is taking to the road for a run of 13 performances throughout September and October.
Based on a true story, the inspiring theatre piece explores the unlikely friendship between a teenage boy who is devoted to free running (Parkour) – the extreme sport that involves navigating obstacles without equipment – and a middle-aged woman with early-onset Parkinson’s disease.
But what can they possibly have in common? Despite living completely opposing lives, a chance encounter leads the two protagonists to realise the answer: they share the desire to move.
Featuring projected imagery and electrifying live Parkour, the show raises awareness of Parkinson’s with wit, while challenging perceptions and giving a realistic insight into the daily struggles that come with living with the condition.
Written by actor and drama teacher, Sue Wylie, the play recounts her personal experience of living with Parkinson’s. Sue, who performs the lead role, explains: “Five years ago shortly after my 50th birthday I was diagnosed with Parkinson’s. After the initial shock I knew I wanted to write about it. I was teaching drama at the time and discovered that a bright but rebellious 16-year-old student in my tutor group was free running on the school roof.
“I was intrigued by the risks he took in his addiction to this extreme sport. How interesting to contrast that with a middle-aged woman whose world of movement is slowly being eroded. What if their paths should accidentally cross and a friendship form? I knew there was a story in there and so Kinetics was born.”
Sue Wylie (left) playing lead character Rose
Through the juxtaposition of the characters the sharp script, full of emotion and humour, unexpectedly draws parallels between two lives that couldn’t seem more opposite. The two learn more important life lessons from one another than they ever could have imagined.
Following the initial success of sold out shows last year, Kinetics received funding from the Arts Council, allowing them to organise the upcoming Autumn 2016 tour. Parkinson’s UK have officially endorsed the play with CEO Steve Ford saying: “Sue’s play offers an inspiring story to which we can all relate.”
Michael J Fox wins apology from magazine over “disturbing” claims about his Parkinson’s
Actor hits out at “disturbing” allegations in magazine article
10 hours ago
World War II weapon antidote could treat Parkinson’s
Researchers at Purdue University, US, are studying a World War II chemical weapon antidote that they believe could be used to treat Parkinson’s. It is believed the antidote, called dimercaprol, may be able to remove acrolein – a toxin that poisons neurons and can lead to the development of Parkinson’s disease. In addition to this, researchers believe dimercaprol can increase the survival rate of brain cells, improve mobility and reduce symptoms of pain. Riyi Shi, professor of neuroscience and biomedical engineering at Purdue University, said: “Our studies show that by removing the toxin (acrolein) from the brain, we are not just reducing the symptoms of Parkinson’s disease but also significantly reversing the damage of Parkinson’s disease. This could actually provide a new treatment for Parkinson’s patients.”
Repurposed cancer drug shows promise for Parkinson’s
Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s. The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far. As part of the research, the study grew brain cells from donated skin cell samples of people living with a rare genetic form of Parkinson’s – this process was then repeated on people with a common non-genetic form of the condition. Researchers found that tasquinimod can block HDAC4, a protein that causes Parkinson’s genes to become inactive. Professor Richard Wade-Martins, co-lead author of the study, said: “We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s.”
Research survey assesses impact of holidays on Parkinson’s symptoms
The Radboud University Medical Center, Netherlands, is seeking participants for an online survey assessing the effects of a holiday on Parkinson’s. The study will assess whether a vacation can have physical and mental benefits for people living with the condition. It will also look at which specific factors, such as temperature and physical activity, can alleviate or increase symptoms. The Michael J Fox Foundation has approved the study’s protocol. Participants can sign up to complete the 20-minute survey online. The survey is open to anyone over 18 who has Parkinson’s and has been on vacation once or more between 1 June 2016 and 30 September 2018. Marjan Faber, the study’s daily supervisor, said: “If the study is able to identify decisive factors, those can act as a starting point for novel approaches in care for people with Parkinson’s disease.” To apply please visit research platform ParkinsonNEXT.